Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

CGC-11047

Generic Name: CGC-11047

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₃₉Cl_₇N_₄

CAS Number: 206991-64-2

Unique Ingredient Identifier: HU43305R7O

Overview

CGC-11047 is a polyamine analog designed to halt cell growth and induce apoptosis.

Background

CGC-11047 is a polyamine analog designed to halt cell growth and induce apoptosis.

Indication

Investigated for use/treatment in lymphoma (unspecified), macular degeneration, prostate cancer, and solid tumors.

Associated Conditions

No associated conditions information available.

Clinical Trials

Study of CGC-11047 (PG-11047) in Subjects With Advanced Refractory Solid Tumors

Phase 1

Completed

Posted: 2008/06/26

Sponsor:

Progen Pharmaceutica...

ID:NCT00705653

Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma

Phase 1

Completed

Posted: 2008/06/26

Sponsor:

Progen Pharmaceutica...

ID:NCT00705874

Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer

Phase 2

Terminated

Posted: 2008/01/03

Sponsor:University of Wiscon...

ID:NCT00585416

Safety of 16.5 mg (3.3%) CGC-11047 Once Every 2 Weeks vs. Once Every 4 Weeks in Patients With CNV Due to AMD

Phase 1

Completed

Posted: 2007/03/13

Sponsor:

Progen Pharmaceutica...

ID:NCT00446654

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy